Predicting AIDS Onset for Individual Patients
in persons with CD4+ counts <200 ce!ls/L and to begin treatment with zidovudine (AZT) to reduce AIDS incidence in persons with counts <500 ce!ls/j.L (10) (11) (12) (13) . Following up early interest in serological markers (14) (15) (16) , recent work has shown that AIDS risk for many (5, 6, (17) (18) (19) (20) but not all (8) (25, 26) suggest the hazard rate may increase less rapidly after eight years after HIV seroconversion. Thus, although mode! 1 may provide an adequate description of risk for three or four years, it may seriously overestimate risk in the longer term. In the previous example, the semiannual hazard for a typical cohort member at year 5 have a lower hazard than older patients (2, 4 (27) . Thus, models of the "natural history" do not apply once a patient has been started on therapy with a drug such as zidovudine.
Models for estimating AIDS risk in treated patients need to be developed. Meanwhile, the work of Reibnegger et a!. contributes to the development of risk models for patient management and for use in clinical trials.
